



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 3, 2022

Berndt Modig  
Chief Executive Officer  
Pharvaris N.V.  
J.H. Oortweg 21  
2333 CH Leiden  
The Netherlands

**Re: Pharvaris N.V.**  
**Registration Statement on Form F-3**  
**Filed on March 2, 2022**  
**File No. 333-263198**

Dear Mr. Modig:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jessica Ansart at (202) 551-4511 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Sophia Hudson